USMCA Pharmaceutical Co.,Ltd.
 
 
R&D
R&D
分类

R&D

R&D

Our company cooperates with top international universities, scientific research institutions, and R&D companies to help pharmaceutical companies realize rapid development of pharmaceutical product technology, help companies implement technology transfer between China and the United States, and grasp the key elements that need to be paid attention to in order to achieve new product launches, product pipeline expansion, and expansion of production capacity, expand the market, reduce costs, shorten time, and reduce investment risks.


At present, the preparation formula (oral) has been obtained as follows:

Alcaftadin Eye Drop 0.25%

Alcaftadin Eye Drop 0.25%

Asenapine

Bimatoprost Eye Drop 0.03%

Bosutinib Tablet

Cabozantinib Tablet

Carboxymethylcellulose Eye Drop 5%

Crizotinib Capsule

Deferasirox Tablet for Suspension

Enzalutamide Capsule

Ibrutinib Capsule

Ivermectine Ointment

Nepafenac Eye Suspension 0.1%

Neratinib Tablet

Nintedanib Capsule



The company is developing more than 100 products, including new drugs, generic drugs, injections and complex dosage forms. Please feel free to contact us for more information!


Statement: The above products are only suitable for R&D usage, and cannot be commercialized in patented countries; otherwise the buyer shall bear all responsibilities.

Contact Us
We are here to meet all your needs, please contact us in time!
Send Us MessageSend Us Message
USMCA Pharmaceutical Co.,Ltd.
Copyright © 2021 USMCA Pharmaceutical Co.,Ltd. All Right  沪ICP备2021014899号-1 Power By:Dijing Technology